NEXGEL Reports Second Quarter 2026 Financial Results
NEXGEL, Inc. reported Q2 2026 revenue of $3.69 million and a net loss of $2.87 million, reflecting the ongoing integration of acquisitions and the formation of its new BioNX Surgical division. The company faced slower-than-expected rollout efforts and supply chain constraints causing product backlogs. It initiated a strategic recall of SilverSeal i…